Epidemiological characteristics and outcomes of COVID-19 in asymptomatic versus symptomatic patients
Vol. 62 No. 4 (2021), COVID-19
Vol. 62 No. 4 (2021)

Epidemiological characteristics and outcomes of COVID-19 in asymptomatic versus symptomatic patients

COVID-19
https://doi.org/10.15167/2421-4248/jpmh2021.62.4.2254
Published 2022-01-04
Habibollah Azarbakhsh
PhD Candidate in Epidemiology, Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran
pdf

Keywords

Covid-19, Asymptomatic infection, Patients with clinical symptoms

Abstract

Background: The clinical manifestations of COVID-19 are different, which can be attributed to asymptomatic carriers, acute respiratory disease and pneumonia with different severities. The aim of this study was to compare the epidemiological characteristics and outcomes of Covid-19 in patients with clinical symptoms versus asymptomatic patients.

Methods: In this retrospective observational study, the epidemiological characteristics of two groups of patients, with clinical symptoms (n= 38,630) and without clinical symptoms who were definitive cases of Covid-19 (n= 2,327) were investigated in the southwestern of Iran. Chi-square test was used to evaluate the differences between qualitative variables in the two study groups.

Results: Of 40,957 patients with Covid-19, 2,327 (5.68%) were asymptomatic, of whom 1391 (59.77%) were males, 1841 patients (79.11%) had a history of contact with definite or suspected cases of covid-19. Symptomatic patients were older than symptomatic cases. Patients with clinical symptoms had higher mortality rate than asymptomatic patients (2.68% in symptomatic patients vs. 0% in asymptomatic patients).

Conclusion: According to the results of our study, the detected viral load in asymptomatic individuals was similar to that of symptomatic patients, indicating that asymptomatic infections can potentially transmit the disease. Therefore, screening and detection of asymptomatic cases is an important and key measure in prevention and early control of covid-19 worldwide.

 

https://doi.org/10.15167/2421-4248/jpmh2021.62.4.2254
pdf

References

1. ALIPOUR A, Ghadami A, ALIPOUR Z, ABDOLLAHZADEH HJQJOHP. Preliminary Validation of the Corona Disease Anxiety Scale (CDAS) in the Iranian Sample. 2020;8(4 (32) #p00880):-.
2. Zhao J, Yang Y, Huang H, Li D, Gu D, Lu X, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. 2020:2020.03.11.20031096.
3. Kalteh EA, Sofizadeh A, Fararooei M, Ghojogh MG, Aljalili S. Measures of Mortality in Coronavirus (COVID-19) Compared with SARS and MERS. Journal of Cellular & Molecular Anesthesia. 2020;5(2):97-101.
4. KALTEH EA, Fararooei M, Aljalili S, Ghelichi-Ghojogh M. Susceptibility to COVID-19 in Pregnant and Breastfeeding Women. Iranian Journal of Public Health. 2020;49:132-3.
5. Khezri R, Valizadeh R, Nozad P, ghelichi ghojogh m. Achieving Vaccine for COVID-19: Hope for AIDS and Hepatitis C Vaccine? Journal of Cellular & Molecular Anesthesia. 2021;6(1):106-7.
6. Parseh B, Kalteh EA, Sheikhi M, ghelichi ghojogh m. Can COVID-19 Be a risk factor for tuberculosis? COVID-19 and tuberculosis. Journal of Cellular & Molecular Anesthesia. 2020;6(1):104-5.
7. Farnoosh G, Alishiri G, Hosseini Zijoud SR, Dorostkar R, Jalali Farahani A. Understanding the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease (COVID-19) Based on Available Evidence - A Narrative Review %J Journal of Military Medicine. 2020;22(1):1-11.
8. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020;53(3):404-12.
9. Han D, Li R, Han Y, Zhang R, Li J. COVID-19: Insight into the asymptomatic SARS-COV-2 infection and transmission. International journal of biological sciences. 2020;16(15):2803-11.
10. Gao Z, Xu Y, Sun C, Wang X, Guo Y, Qiu S, et al. A systematic review of asymptomatic infections with COVID-19. J Microbiol Immunol Infect. 2021;54(1):12-6.
11. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-51.
12. Kimball A, Hatfield KM, Arons M, James A, Taylor J, Spicer K, et al. Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility - King County, Washington, March 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):377-81.
13. Kim GU, Kim MJ, Ra SH, Lee J, Bae S, Jung J, et al. Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19. Clin Microbiol Infect. 2020;26(7):948.e1-.e3.
14. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA. 2020;323(14):1406-7.
15. Tong ZD, Tang A, Li KF, Li P, Wang HL, Yi JP, et al. Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis. 2020;26(5):1052-4.
16. Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. MMWR Morbidity and mortality weekly report. 2020;69(14):411-5.
17. Qian G, Yang N, Ma AHY, Wang L, Li G, Chen X, et al. COVID-19 Transmission Within a Family Cluster by Presymptomatic Carriers in China. Clin Infect Dis. 2020;71(15):861-2.
18. Luo SH, Liu W, Liu ZJ, Zheng XY, Hong CX, Liu ZR, et al. A confirmed asymptomatic carrier of 2019 novel coronavirus. Chin Med J (Engl). 2020;133(9):1123-5.
19. Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2020;25(10):2000180.
20. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. 2020;382(12):1177-9.
21. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung SM, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis. 2020;94:154-5.
22. Ki M. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea. Epidemiol Health. 2020;42:e2020007.
23. Wang L, Wang Y, Ye D, Liu Q. Review of the 2019 novel coronavirus (SARS-CoV-2) based on current evidence. Int J Antimicrob Agents. 2020;55(6):105948.
24. Tang YW, Schmitz JE, Persing DH, Stratton CW. Laboratory Diagnosis of COVID-19: Current Issues and Challenges. J Clin Microbiol. 2020;58(6).
25. Ganji A, Mosayebi G, Khaki M, Ghazavi A. A Review of the 2019 Novel Coronavirus (Covid-19): Immunopathogenesis, Molecular Biology and Clinical Aspects %J Journal of Arak University of Medical Sciences. 2020;23(1):8-21.
26. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102-8.
27. Zhao J, Yang Y, Huang H-P, Li D, Gu D-F, Lu X-F, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. 2020:2020.03.11.20031096.
28. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci. 2020;63(5):706-11.